Abstract:Background: Spain has been severely affected by the COVID-19 epidemic, with 195,944 persons infected and 20,453 deaths at the time of writing. Older people with respiratory or cardiac conditions are most at risk.
Objective: The aim was to compare respiratory symptoms in nursing home residents and patients with uncontrolled asthma, who are considered vulnerable to COVID-19.
Methods: We studied 134 nursing home residents and 139 patients with uncontrolled asthma, groups vulnerable to COVID-19. Demographic charac… Show more
“… 10 Accordingly, other large studies and meta-analyses suggested that asthma patients may have a lower risk of severe COVID-19. 1 , 9 , 29 This could be related to the effect of atopy and type 2 inflammation in allergic patients. 30 An Italian study found a decreased risk of severe COVID-19 disease in patients with atopic disease.…”
Section: Resultsmentioning
confidence: 99%
“…The authors also found a significant difference in SARS-CoV-2 infections between asthma patients treated with ICS and nursing home residents not treated with ICS. 29 …”
Coronavirus disease 2019 (COVID-19) continues to spread across the world. Since the beginning of the pandemic, the question of whether asthma is a risk factor for getting the infection or for poor outcomes motivated a great debate. In the field of severe asthma and its treatment during COVID-19 pandemic, several issues are also pending. A literature review focused on the management of severe asthma patients in the context of COVID-19 is performed. The available evidence suggests that severe asthma patients do not have an increased risk of poor COVID-19 outcomes and that it is safe to treat asthmatic patients with inhaled corticosteroids (ICS) and biologics during the pandemic, even though some studies indicate that high doses of ICS may predispose to COVID-19. The chronic use of oral corticosteroid (OCS) might be associated with poor COVID-19 outcomes, although there is no complete agreement. There is very limited evidence concerning the use of triple therapy for asthma in the context of this pandemic. Ultimately, severe asthma patients should maintain their medication during the COVID-19 pandemic, including biologic agents. More studies are needed to address the role of asthma medications and asthma’s different phenotypes on the incidence and course of COVID-19.
“… 10 Accordingly, other large studies and meta-analyses suggested that asthma patients may have a lower risk of severe COVID-19. 1 , 9 , 29 This could be related to the effect of atopy and type 2 inflammation in allergic patients. 30 An Italian study found a decreased risk of severe COVID-19 disease in patients with atopic disease.…”
Section: Resultsmentioning
confidence: 99%
“…The authors also found a significant difference in SARS-CoV-2 infections between asthma patients treated with ICS and nursing home residents not treated with ICS. 29 …”
Coronavirus disease 2019 (COVID-19) continues to spread across the world. Since the beginning of the pandemic, the question of whether asthma is a risk factor for getting the infection or for poor outcomes motivated a great debate. In the field of severe asthma and its treatment during COVID-19 pandemic, several issues are also pending. A literature review focused on the management of severe asthma patients in the context of COVID-19 is performed. The available evidence suggests that severe asthma patients do not have an increased risk of poor COVID-19 outcomes and that it is safe to treat asthmatic patients with inhaled corticosteroids (ICS) and biologics during the pandemic, even though some studies indicate that high doses of ICS may predispose to COVID-19. The chronic use of oral corticosteroid (OCS) might be associated with poor COVID-19 outcomes, although there is no complete agreement. There is very limited evidence concerning the use of triple therapy for asthma in the context of this pandemic. Ultimately, severe asthma patients should maintain their medication during the COVID-19 pandemic, including biologic agents. More studies are needed to address the role of asthma medications and asthma’s different phenotypes on the incidence and course of COVID-19.
“…These findings suggest that ICS may reduce the risk of developing of COVID-19 in response to SARS-CoV-2 infection or reducing the severity of the disease. Recently, several clinical studies also showed conflict results about this issue whether ICS exhibits a protect or aggravating effect against SARS-CoV-2 infections [24] , [25] , [26] , [27] , [28] , [29] , [30] . Although several meta-analyses assessed the association between ICS and the outcome of COVID-19 [31] , [32] , none of them focused on the effect of ICS on the risk of SARS-CoV-2 infections.…”
“…We did not perform separate analyses for the use of inhaled steroids. While these medications have been shown to have some impact on the course of COVID-19 [35], we felt that separating the effect of inhaled steroids from the much stronger impact of routinely administered intravenous dexamethasone per Infectious Disease Society of America treatment guidelines would be difficult [36,37].…”
Introduction: COVID-19 is a major health threat around the world causing hundreds of millions of infections and millions of deaths. There is a pressing global need for effective therapies. We hypothesized that leukotriene inhibitors (LTIs), that have been shown to lower IL6 and IL8 levels, may have a protective effect in patients with COVID-19. Methods: In this retrospective controlled cohort study, we compared death rates in COVID-19 patients who were taking a LTI with those who were not taking an LTI. We used the Department of Veterans Affairs (VA) Corporate Data Warehouse (CDW) to create a cohort of COVID-19-positive patients and tracked their use of LTIs between November 1, 2019 and November 11, 2021. Results: Of the 1,677,595 cohort of patients tested for 189,195 patients tested positive for COVID-19. Forty thousand seven hundred one were admitted. 38,184 had an oxygen requirement and 1214 were taking an LTI. The use of dexamethasone plus a LTI in hospital showed a survival advantage of 13.5% (CI: 0.23%-26.7%; p < 0.01) in patients presenting with a minimal O 2 Sat of 50% or less. For patients with an O 2 Sat of <60 and <50% if they were on LTIs as outpatients, continuing the LTI led to a 14.4% and 22.25 survival advantage if they were continued on the medication as inpatients. Conclusions: When combined dexamethasone and LTIs provided a mortality benefit in COVID-19 patients presenting with an O 2 saturations <50%. The LTI cohort had lower markers of inflammation and cytokine storm.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
